Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MESA LABORATORIES INC /CO/MLAB · Entity 5221 | SVP Operations | June 18, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MESA LABORATORIES INC /CO/
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,377 |
Ending reported balance
After 2026-06-22 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-06-18 · Exercise / conversion · Acquired 844 · Balance 4,554 Row 2 · 2026-06-18 · Exercise / conversion · Acquired 2,480 · Balance 7,034 Row 3 · 2026-06-18 · Grant · Acquired 1,859 · Balance 8,893 F5: Shares represent common stock of Mesa Labs issued upon release of performance share units issued under the FY24-FY26 performance share unit program Row 4 · 2026-06-22 · Sale · Disposed 2,516 · Balance 6,377 |
| Restricted Stock Units - 7SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-18 · Exercise / conversion · Disposed 844 · Balance 0 F1: Each RSU represents a contingent right to receive one share of the Issuer's common stock F2: RSUs that vested June 21, 2024 and each of the next two anniversary dates F3: Not Applicable |
| Restricted Stock Units - 8SEC Table II · derivative / convertible security · Expires 2025-06-18 | Direct | 2,480 |
Reported balance
After 2026-06-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-18 · Exercise / conversion · Disposed 2,480 · Balance 2,480 F1: Each RSU represents a contingent right to receive one share of the Issuer's common stock F3: Not Applicable F4: RSUs that vest 1/3 on June 15, 2026 and each of the next 2 anniversary dates |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive one share of the Issuer's common stock
F2: RSUs that vested June 21, 2024 and each of the next two anniversary dates
F3: Not Applicable
F4: RSUs that vest 1/3 on June 15, 2026 and each of the next 2 anniversary dates
F5: Shares represent common stock of Mesa Labs issued upon release of performance share units issued under the FY24-FY26 performance share unit program
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2020 Filed Jun 17, 2020 16:34 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | Exercise / conversionRestricted Stock Units - 1 · Derivative | 70 | $0.00 | $0.00 |
DisclosureSEC source: 0001228924-20-000018 · primary_doc.xml · derivative · entry 3 Archbold Brian David · CIK 0001776947 · SVP Continuous Improvement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210 Underlying: Common Stock · 70 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock F2 · derivative.exercise_date: RSUs that vest 1/5 on June 15, 2019 and each of the next four anniversary dates F3 · derivative.expiration_date: Not Applicable Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 16:34 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | Tax withholdingCommon Stock | 32 | $226.72 | $7,255.04 |
DisclosureSEC source: 0001228924-20-000018 · primary_doc.xml · nonDerivative · entry 2 Archbold Brian David · CIK 0001776947 · SVP Continuous Improvement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270 F4 · shares: Represents shares of common stock retained by Mesa Labs for tax withholding purposes in connection with the net-settlement on the issuance of shares of common stock in respect to vested RSUs. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 16:34 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | Exercise / conversionCommon Stock | 70 | $0.00 | $0.00 |
DisclosureSEC source: 0001228924-20-000018 · primary_doc.xml · nonDerivative · entry 1 Archbold Brian David · CIK 0001776947 · SVP Continuous Improvement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2020 Filed Feb 21, 2020 22:55 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | SaleCommon Stock | 123 | $268.19 | $32,987.49 |
DisclosureSEC source: 0001228924-20-000004 · primary_doc.xml · nonDerivative · entry 1 Archbold Brian David · CIK 0001776947 · SVP of Continuous Improvement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232 Read SEC document |
| June 15, 2019 Filed Jun 18, 2019 16:30 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | Exercise / conversionRestricted Stock Unit - 1 · Derivative | 70 | $0.00 | $0.00 |
DisclosureSEC source: 0001228924-19-000029 · primary_doc.xml · derivative · entry 3 Archbold Brian David · CIK 0001776947 · SVP of Continuous Improvement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280 Underlying: Common Stock · 70 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock F2 · derivative.exercise_date: Restricted Stock Units that vest 1/5 on June 15, 2019 and each of the next four June 15's thereafter F3 · derivative.expiration_date: Not Applicable Read SEC document |
| June 15, 2019 Filed Jun 18, 2019 16:30 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | Tax withholdingCommon Stock | 25 | $202.39 | $5,059.75 |
DisclosureSEC source: 0001228924-19-000029 · primary_doc.xml · nonDerivative · entry 2 Archbold Brian David · CIK 0001776947 · SVP of Continuous Improvement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355 Read SEC document |
| June 15, 2019 Filed Jun 18, 2019 16:30 UTC | MESA LABORATORIES INC /CO/ MLAB · Entity 5221 | Exercise / conversionCommon Stock | 70 | $0.00 | $0.00 |
DisclosureSEC source: 0001228924-19-000029 · primary_doc.xml · nonDerivative · entry 1 Archbold Brian David · CIK 0001776947 · SVP of Continuous Improvement 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.